Company / Working Capital
Arrowhead Pharmaceuticals Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$755.2M
FY2025
5-year range
$238.1M / $755.2M
FY2021-FY2025
Trend
+27.5%
vs FY2024
Sector context
#56 of 213
Health Care
What the data says
At $755M, Arrowhead Pharmaceuticals's working capital ranks #56 of 213 in the Health Care sector. Working Capital has increased for 4 consecutive years, from $238M in FY2021 to $755M in FY2025.
Based on SEC 10-K filings.
$755M in FY2025 with a 5-year CAGR of +21.8%.
Improved from $314M to $755M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +41.5%
- 5-Year CAGR
- +21.8%
- 10-Year CAGR
- -
Sector benchmark
#56 of 213 in Health CareTop 26% of 213This company $755.2M Sector average $934.6M
▼
-19.2% below sector average
Key checks
Key Insights
- Arrowhead Pharmaceuticals's working capital has grown for 4 consecutive years.
- 5-year CAGR of +21.8%, indicating consistent growth.
- In FY2025, working capital increased 27.5% year-over-year.
- Ranks #56 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $755.2M | +27.5% |
| FY2024 | $592.3M | +88.6% |
| FY2023 | $314.1M | +17.9% |
| FY2022 | $266.4M | +11.9% |
| FY2021 | $238.1M | -15.5% |
| FY2020 | $281.7M | +67.5% |
| FY2019 | $168.2M | +153.3% |
| FY2018 | $66.4M | +35.0% |
| FY2017 | $49.2M | -24.1% |
| FY2016 | $64.9M | -25.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026